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Abstract 
Objective. Investigate the impact of modulating B cell FcγRIIb expression on 
atherosclerosis. 
Approach and results. Western diet-induced atherosclerosis was assessed in Ldlr-/- 
or Apoe-/- mice with B cell-specific overexpression of FcγRIIb or with an FcγRIIb 
promoter mutation that alters FcγRIIb expression in germinal center (GC) B cells. In 
males, overexpression of FcγRIIb on B cells severely reduced activated, class 
switched B cell responses, as indicated by reductions in GC B cells, plasma cells 
and serum IgG but not IgM antibodies. Male mice overexpressing FcγRIIb developed 
less atherosclerosis, suggesting a pathogenic role for GC B cell IgG responses. In 
support of this hypothesis, male mice with a promoter polymorphism-driven reduction 
in FcγRIIb on GC B cells but not plasma cells have a converse phenotype of 
enhanced GC responses and IgG2c antibodies, and enhanced atherosclerosis. 
IgG2c significantly enhanced TNF secretion by CD11b+ CD11c+ cells expressing 
the high affinity receptor FcγRIV. In females, overexpression of FcγRIIb on B cells 
not only reduced GC B cell responses but also substantially reduced B-1 cells and 
IgM antibodies, which translated into acceleration of atherosclerosis. Promoter-
driven reduction in FcγRIIb did not alter GC B cell responses in females and 
therefore, had no impact on atherosclerosis. 
Conclusions. B cell FcγRIIb differentially alters pro-atherogenic adaptive GC B cell 
and athero-protective innate B-1 responses in male and female mice fed a western 
diet. Our results highlight the importance of a better understanding and ability to 
selectively target B cell responses in future immunotherapeutic approaches against 
human cardiovascular disease. 
 
 
 
Abbreviations: AP-1 - activating protein-1, BAFF  - B cell activating factor of the 
TNF family, Btg - B cell transgenic, FcγR - Fcγ receptors, GC - germinal center, MZ - 
marginal zone, NZB - New Zealand black, OSE - oxidation-specific epitopes, FO - 
follicular, PC - phosphorylcholine, Tfh - Follicular helper T cell. 
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Introduction 
Despite significant progress in reducing mortality rates, the incidence and morbidity 
associated with cardiovascular disease, most commonly caused by underlying 
atherosclerosis, continues to represent a leading global health concern. 
Atherosclerosis is driven by an aberrant response to LDL accumulation by both 
vascular wall cells and invading immune cells. The modification of LDL is 
hypothesised to drive these non-resolving inflammatory cycles. B cell responses 
have long been associated with atherosclerosis, particularly antibody responses to 
oxidized LDL1, 2. IgM antibodies to pro-inflammatory oxidation-specific epitopes 
(OSE) are produced by innate-like B-1 cells, which exhibit atheroprotective 
properties3. In contrast, autoantibody-driven autoimmune diseases, such as systemic 
lupus erythematosus, are associated with accelerated atherosclerosis progression, 
although the mechanisms linking the two diseases are still under investigation4. 
Autoimmunity is associated with a break in tolerance, i.e. a failure of checkpoints 
during B cell or T cell activation, and production of class-switched IgG, IgE or IgA 
antibodies to autoantigens5. B cell depletion therapy using anti-CD20 antibodies is 
effective against some autoimmune diseases and also mitigates cardiovascular 
disease in experimental models of atherosclerosis6, 7 , myocardial infarction8, 
abdominal aortic aneurysm9 and hypertension10.  
A major effector mechanism of IgG antibodies is binding Fcγ receptors (FcγR) on the 
cell surface of immune cells, distinguishing IgG functions from other isotypes such as 
IgM. There are several activating receptors (FcγRI, III and IV in mice) expressed on 
monocytes, macrophages, dendritic cells and neutrophils, which promote pro-
inflammatory functions via immunoreceptor tyrosine-based activation motif-mediated 
signalling pathways11. In contrast, there is a single inhibitory receptor, FcγRIIb, which 
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antagonises activating FcγR signalling through its intracellular immunoreceptor 
tyrosine-based inhibitory motif domains12. FcγRIIb is also expressed on B cells, 
where it regulates B cell responses at multiple points12. In fact in humans, the major 
subtype expressing FcγRIIb is B cells11. Co-ligation of the B cell receptor and 
FcγRIIb by antigen-IgG immune complexes raises the activation threshold compared 
to soluble antigen, limiting B cell responses. On plasma cells and B-1 cells, FcγRIIb 
has a direct pro-apoptotic influence that is continuously counteracted by survival 
factors such as B cell activating factor of the TNF family (BAFF)13, 14. FcγRIIb genetic 
mutations are associated with systemic lupus erythematosus and also with total IgG 
levels in humans, suggesting an important role for FcγRIIb in B cell-dependent 
regulation of disease15, 16. Investigations into the role of FcγRIIb in atherosclerosis 
have so far focused on Fcgr2b-/- mice, with conflicting reports. In contrast to several 
previous studies that reported enhanced atherosclerosis17, 18, Harmon et al found 
decreased atherosclerosis in Fcgr2b-/-Apoe-/- mice19. A subsequent study from 
Merched et al using Fcgr2b-/- bone marrow transfer into Ldlr-/- mice found increased 
atherosclerosis20, supporting the previous studies. Considering that FcγRIIb 
expression on different cell types could have divergent functions, alternative 
approaches are necessary to provide additional insights. Since opposing roles for 
different B cell subsets in atherosclerosis have been revealed in several recent 
studies21-25, we investigated the role of B cell FcγRIIb in atherosclerotic plaque 
development. Our data implicates FcγRIIb on B cells as an important regulator of 
atherosclerosis and reveals novel insights into how B cells respond to and regulate 
atherosclerosis. 
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Methods 
The data that support the findings of this study are available from the corresponding 
author upon reasonable request. 
Mice 
Ldlr-/- (002207) and Apoe-/- (002052) mice were originally obtained from the Jackson 
laboratory. FcγRIIb-B cell transgenic mice (Btg) and FcγRIIbΔAP-1 mice were 
previously described13, 26, both strains (created using C57BL6 embryos) were 
crossed to Apoe-/- mice. Btg mice were maintained via transgenic x non-transgenic 
breeding. Control (FcγRIIb-WT; “WT”) mice were non-transgenic Apoe-/- littermates. 
Heterozygous FcγRIIb-ΔAP-1 (+/ΔAP-1) mice were used as breeders and data from 
control (‘BL6’; +/+ or +/ΔAP-1) and homozygous mutant (ΔAP-1/ΔAP-1) littermates is 
presented. Bone marrow transfer experiments were performed as previously 
described27. Mice received western diet (21% fat; 0.15% cholesterol; Scientific Diet 
Services) for 6 or 12 weeks. Mice from different experimental groups were co-
housed for atherosclerosis experiments. For IgM half-life experiments, male and 
female Apoe-/- mice were injected i.v. with 200 µl of gender-matched Balb/c mouse 
serum (with normalized IgM concentration). Blood samples were collected 4, 25 and 
48h post injection from the saphenous vein.  Mice were kept under a 12/12 hour 
light/dark cycle with access to food (DS150; SAFE) and water ad libitum. Cage 
bedding was from Datesand. All experiments were conducted under license and 
within the institutional guidelines of the University of Cambridge and adhered to the 
recommendations set out by the AHA. 
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Plaque and serum analysis 
To assess plaque size and composition, aortic root cryosections were stained with 
Oil red O, hematoxylin and eosin, picrosirius red, α-smooth muscle actin (all Sigma), 
CD3 (Dako) or MOMA2 (Biorad). Images were analyzed using ImageJ (NIH). 
Cellularity was determined by quantifying the proportion of nuclear-stained area 
within plaques (Hoechst staining). Serum total and oxidation-specific epitope (OSE) 
antibodies were analyzed using kits from Bethyl labs or as previously described28. 
Total cholesterol was quantified using a cholesterol RTU kit (Biomerieux) and serum 
B cell activating factor (BAFF) by ELISA (BioTechne).  
Immune cell phenotyping 
Flow cytometry of single cell suspensions was performed as previously described. 
Flow cytometry antibodies are detailed in Supplemental Table 1 and gating 
strategies are outlined in Supplemental Figure I. In some experiments, B-1 cells 
were alternatively gated as B220lo IgM+ CD43+ CD5+ and germinal center (GC) B 
cells as B220+ IgM+ CD95+ GL-7+. In vitro B cell proliferation was assayed using 
splenic B cells purified by negative selection (Miltenyi) after stimulation for 72h with 
anti-IgM whole IgG or Fab’ fragments (Southern Biotech). B-1 cells were enriched by 
fluorescence-activated cell sorting from peritoneum as B220+ IgM+ CD43+ CD23- 
cells. Apoptosis was assessed using an annexin V kit (Life technologies) and flow 
cytometry. Polystyrene beads (BD) were spiked into cultures prior to staining and 
used to normalize samples so that absolute numbers of remaining live cells (Annexin 
V- propidium iodide-) could be quantified. IgM production was stimulated in B1 cell 
cultures by incubating with IL-5 (5ng/ml; Peprotech) and BAFF (10ng/ml; Biotechne). 
CD11c+ CD11b+ macrophages/dendritic cells were generated with GM-CSF 
(20ng/ml; Biolegend) and stimulated with IFN-γ (2 ng/ml; Biolegend) in 96 well plates 
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coated with mouse IgG2c or IgG1 (Biolegend) or treated with polystyrene beads 
(anti-mouse κ compbeads, BD) coated with mouse IgG2c or IgG1. Supernatants 
were analyzed for TNF levels by ELISA (Biotechne) after 48h. 
Statistical Analysis 
Data was analyzed in GraphPad Prism (La Jolla, CA, USA); technical dropout during 
data collection is indicated in figure legends. Statistically significant outliers (Grubb’s 
test) were excluded where indicated in figure legends. Two group comparisons were 
analyzed using unpaired t test or Mann Whitney U test for data sets not passing 
normality (D’Agostino and Pearson test) or not having equal variances (F Test). 
Experiments with 3 or more groups were analyzed using one-way ANOVA with 
Newman-Keuls multiple comparison test. Plaque size profiles were analyzed using 
two-way ANOVA. A p value <0.05 was considered significant. The number of 
asterisks indicate the p value level (* <0.05; **<0.01, *** <0.005; ****<0.0001). 
Results 
B cell overexpression of FcγRIIb in male mice reduces atherosclerosis  
Overexpression of FcγRIIb on B cells, mimicking the endogenous upregulation that 
occurs during B cell activation, was shown to protect mice in models of arthritis and 
SLE13, 29. We therefore designed experiments to examine the effect of B cell FcγRIIb 
overexpression on atherosclerosis using this previously described FcγRIIb-B cell 
transgenic (“Btg”) mouse. The transgene results in specifically elevated FcγRIIb on B 
cells but not myeloid (CD11b+) cells (Figure 1A). We confirmed the functional impact 
of this by measuring the response to B cell activation in vitro with anti-B cell receptor 
(anti-IgM) antibodies with or without the FcγRIIb-recruiting Fc portion. The 
proliferation in response to anti-IgM IgG antibodies was severely attenuated in B 
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cells from Btg Apoe-/- mice. When anti-IgM Fab’ fragments (lacking Fc receptor 
binding capacity) were used, there was a much smaller difference between WT and 
Btg B cells (Figure 1B), with the residual difference potentially due to enhanced levels 
of apoptosis in Btg B cells. Indeed, in vivo, Btg mice have lower proportions of 
follicular B cells but similar proportions of other B-2 cell subsets (Figure 1C), and 
express elevated levels of pro-apoptotic Fas (Supplemental Figure IIA).  
We first analysed the impact on atherosclerosis using bone marrow transplant from 
Btg or non-transgenic littermate control mice into irradiated Ldlr-/- mice. 
Atherosclerotic plaque size was reduced in Ldlr-/-/Btg mice compared to Ldlr-/-/WT 
mice (Figure 1D). Total cholesterol, body weights, and circulating monocyte numbers 
were not different between groups (Supplemental Figure IIB-D). Using the same Ldlr-
/- chimeric model, we did not observe any impact on atherosclerosis using mice with 
FcγRIIb overexpression driven by the macrophage-specific CD68 promoter 29 
(Supplemental figure IIE-H), suggesting a more influential role for FcγRIIb-mediated 
control of B cells on atherosclerosis. Based on these results, we created Btg Apoe-/- 
mice and analysed the impact of western diet-induced atherosclerosis in male mice. 
Atherosclerosis in the aortic root was similar after 6 weeks but significantly reduced 
in Btg Apoe-/- mice after 12 weeks of western diet (Figure 1E and Supplemental figure 
IIIA). Again, there were no significant differences in total cholesterol, body weights or 
circulating monocytes between groups (Supplemental Figure IIIB-D). There were no 
significant differences in spleen and bone marrow cellularity between control and Btg 
mice (supplemental figure IIIE+F).  Further analysis of the atherosclerotic plaques 
revealed that there were no significant differences in key plaque components such 
as macrophages, smooth muscle cells, necrotic core or collagen (Supplemental 
Figure IIIG-J).  
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B cell overexpression of FcγRIIb reduces GC-dependent antibody responses  
B cells regulate atherosclerosis via multiple mechanisms (reviewed in2), including 
regulation of T cells 6, 7, 22, 24, 30, via the cytokine BAFF 31 or via antibody responses27, 
32, 33. We therefore analysed whether any of these mechanisms could explain the 
impacts on atherosclerosis in the Btg models. Previously, B cell depletion strategies 
led to reduced CD3+ staining in plaques and reduced T cell activation6, 24. Here, 
plaque CD3+ T cell levels were diminished in Ldlr-/-/Btg mice but not in Btg Apoe-/- 
mice (Supplemental Figure IVA-B), despite a significant reduction in activated 
effector memory T cells (Tem) in the spleen of both Ldlr-/-/Btg and Btg Apoe-/- mice 
compared to their respective controls (Supplemental Figure IVC-D). We recently 
found an important protective role for BAFF in atherosclerosis which we suggest 
acted via macrophage-expressed TACI31; this provides an alternative mechanism for 
the protective effect of B cell depletion, which results in high BAFF levels30. In Btg 
mice, BAFF levels were lower than control mice (Supplemental Figure IV-E). We 
then turned to the humoral response, A major phenotype of these mice is decreased 
plasma cell survival13, which prompted us to analyse the humoral responses thought 
to play a role in atherosclerosis2. Proportions of bone marrow plasma cells were 
significantly reduced in Btg Apoe-/- mice compared to control littermates (Figure 2A). 
In agreement with this, total IgG levels in serum were decreased in Btg Apoe-/- mice 
(Figure 2B) and Ldlr-/-/Btg mice (Supplemental Figure IV-F) compared to respective 
controls, whereas total IgM levels were not affected (Figure 2C and Supplemental 
Figure IV-G). FcγRIIb also directly inhibits GC B cells (by inhibiting BCR 
signalling;26), which produce the class-switched antibody response, and B-1 cells (by 
promoting apoptosis;14), which mainly produce IgM. In accordance with the antibody 
data, GC B cells were reduced in Btg Apoe-/- mice compared to Apoe-/- controls 
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whereas proportions of B-1 cells were not different (Figure 2D-E). The specific 
isotypes IgG1 and IgG2c are largely GC-dependent and known to be increased in 
atherosclerotic mice (18, authors unpublished data). The levels of both IgG1 and 
IgG2c were reduced in Btg Apoe-/- mice (Figure 2F-G). We also found similar 
reductions in MDA-LDL-binding IgG1 and IgG2c (Figure 2H). In contrast, there were 
no differences in levels of IgM with specificities associated with B-1 cells, including 
MDA-LDL, anti-phosphorylcholine (PC) or the specific anti-PC T15 clonotypic 
antibodies (Figure 2I). We also detected the same reductions in total and MDA-LDL 
IgG2c in Ldlr-/-/Btg mouse serums, without alteration of IgG1 and IgM levels 
(Supplemental Figure IV H-J). We concluded that B cell FcγRIIb-driven reduction in 
atherosclerosis was associated with reductions in systemic CD4+ T cell responses 
and IgG2c class-switched antibody responses. 
Selective decrease of FcγRIIb in germinal center B cells increases 
atherosclerosis 
The decrease in class-switched antibodies in Btg mice could be due to FcγRIIb acting 
directly on GC B cells, on which it inhibits activation, and/or on plasma cells, on 
which it promotes apoptosis. We therefore sought out a way to separate the impact 
of FcγRIIb on GC B cells from its role on plasma cells. Inbred mouse strains as well 
as wild type strains from around the world display distinct haplotypes at the FcγRIIb 
locus 26. The haplotype carried by New Zealand black (NZB) mice lacks an activating 
protein-1 (AP-1) binding site in the proximal promoter region and was reported to 
lead to defective upregulation of FcγRIIb specifically upon GC B cell recruitment26. 
By ‘knocking in’ the NZB haplotype FcγRIIb promoter sequence into the C57BL/6 
mouse genome, ‘FcγRIIbΔAP-1’ mice display decreased FcγRIIb expression on GC B 
cells and consequently enhanced GC formation26. Importantly for our studies, 
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FcγRIIbΔAP-1 mice have a very mild autoimmune phenotype with no overt clinical 
signs up to 14 months, with glomerular IgG deposition but no decrease in kidney 
function evident at that age26. We crossed FcγRIIbΔAP-1 mice to the Apoe-/- 
background, and confirmed comparatively reduced FcγRIIb levels on GC B cells in 
FcγRIIbΔAP-1 compared to control (FcγRIIbBL6) littermates (Figure 3A). Some 
reduction was also detectable in transitional cells entering the spleen and on naïve 
follicular cells, however no difference was detected in MZ, B-1 or plasma cells, which 
all have higher expression levels than naïve B cells (Figure 3A), suggesting that the 
AP-1 binding site is not critical for upregulation in those cells. Indeed, the B cell 
compartment was grossly normal in FcγRIIbΔAP-1 compared to WT controls, with no 
differences in proportions of different B cell subsets (Supplemental Figure VA). 
Atherosclerosis-prone FcγRIIbΔAP-1 mice displayed a significant enhancement of GC 
B cells, follicular helper T (Tfh) cells (that participate in the GC reaction) and 
circulating IgG2c antibodies compared to FcγRIIbBL6 littermates (Figure 3B-C and 
Supplemental Figure VB). Serum IgG1 levels were not different (Figure 3D). In 
support of a proatherogenic role of enhanced GC responses, FcγRIIbΔAP-1 mice had 
bigger atherosclerotic plaques compared to FcγRIIbBL6 littermates (Figure 3E).  This 
was not associated with changes in plasma cholesterol, body weight or circulating 
monocytes (Supplemental Figure VC-E). Atherosclerotic plaques were more cellular, 
and contained more macrophages (Figure 3F-G), whereas CD3+ T cell proportions 
were similar to control mice (Supplemental Figure VF). Taken together, GC-B cell 
intrinsic FcγRIIb levels control a pro-atherogenic response. 
IgG2c induces TNF in FcγRIV-expressing CD11c+ CD11b+ cells 
To understand the potential for IgG2c to directly regulate atherosclerosis, we 
analysed the expression of its pro-inflammatory receptor FcγRIV (which is mainly 
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expressed in myeloid cell subsets). FcγRIV was most highly expressed on Ly6Clo 
monocytes in the blood, consistent with previous reports34 (Figure 4A). In the 
atherosclerotic mouse aorta, CD45+ CD11b+ CD11c+ cells (monocyte-derived 
macrophages/dendritic cells) expressed high levels of FcγRIV (Figure 4B-C). To 
investigate the response of these cells to IgG2c in vitro, we cultured CD11b+ CD11c+ 
MHCII+ cells using bone marrow monocytes differentiated with GM-CSF (moDCs). 
MoDCs upregulated FcγRIV in response to IFNγ, a known pro-atherosclerotic 
cytokine (Figure 4D). We then investigated the effect of mouse IgG2c and IgG1 
antibodies as immune complexes on moDC activation, measured by TNF secretion, 
in two ways. Firstly, we pre-coated culture plates with either IgG2c or IgG1 and then 
added moDCs in the presence of IFNγ. After 48h, IFNγ-treated moDCs alone 
produced very low levels of TNF (Figure 4E). MoDCs cultured in IgG2c-coated wells 
produced significantly more TNF than IgG1, supporting a more pro-inflammatory 
effect on these cells (Figure 4E). Next, we made antibody-coated particles (that 
could mimic antibody-coated oxLDL or necrotic debris in plaques) using polystyrene 
beads coated with IgG2c or IgG1. Coated beads (or control uncoated beads) were 
incubated with IFNγ-pre-treated moDCs and TNF production quantified. Uncoated 
beads induced some TNF production above IFNγ-treated moDCs without beads 
(Figure 4F), however, IgG2c-coated beads produced increased TNF, whereas IgG1 
coated beads did not (Figure 4F). This data supports the notion that IgG2c 
antibodies could enhance inflammatory responses by plaque macrophages or 
dendritic cells. 
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B cell FcγRIIb overexpression in female mice decreases IgM and enhances 
atherosclerosis 
We were initially surprised that IgM levels were not modulated in Btg mice, since 
FcγRIIb should also negatively regulate IgM+ plasma cells and has also been shown 
to promote B-1 cell apoptosis14. Indeed, when we purified B-1 cells from Btg Apoe-/- 
and Apoe-/- mice and incubated them in control or anti-FcγRIIb coated plates, Btg 
Apoe-/- B cells were more prone to undergo apoptosis (Supplemental Figure VI A; 
assessed by Annexin V exposure; see methods). This suggests that in vivo in male 
Btg mice, the pool of IgM-secreting B-1 cells or other IgM-producing B cells was 
renewed rapidly enough from resting B cells to compensate for a shorter lifespan of 
IgM antigen-secreting cells (ASC). However, when we investigated female Btg Apoe-/- 
mice, we did observe a reduction in B-1 cells, total IgM levels and MDA-LDL IgM 
levels (Figure 5A-C), with other B cell parameters similar to males (data not shown). 
Indeed, as the major observed difference between genders, the reduced IgM in 
females appears to be critical to the outcome of atherosclerotic plaque development, 
since female Btg Apoe-/- had significantly enhanced atherosclerosis (Figure 5D) in 
contrast to the male counterparts (Figure 1), but similar to antibody-deficient Xbp1cKO 
mice27 and B cell (and therefore antibody)-deficient mice35. The plaques of Btg Apoe-/- 
female mice had larger necrotic cores (Supplemental Figure 6B). Therefore, a 
combined deficiency in IgG and IgM may provide an explanation for the accelerated 
atherosclerosis in female mice in this setting.  
Male and Female Apoe-/- mice display different B1 cell dynamics in vivo and in 
vitro  
We investigated several possibilities that could explain the gender disparity. There 
was no gender-specific difference in FcγRIIb over-expression levels in Btg mice, or in 
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baseline FcγRIIb levels in control littermates on B1 cells (Supplemental Figure VI-C). 
We did observe, by analysing past data from multiple experiments and strains on the 
Apoe-/- background, that female Apoe-/- mice had higher B1 cell numbers in the 
spleen (figure 6A). A higher proportion of female B1 cells stained positive for the 
proliferation marker Ki67 than in male B1 cells in the spleen (figure 6B), where B1 
cells migrate to self-renew or differentiate into plasma cells21, 36. Despite the 
difference in splenic B1 cell levels between males and females, which was highly 
reproducible, there were no consistent differences in total or OSE-specific IgM levels 
or IgM-producing plasma cells between male and female Apoe-/- mice (data not 
shown). We hypothesised that a larger supply of B1 cells is required to maintain 
similar steady state levels of IgM in females than in males, at least in the context of 
the high demand expected in atherosclerotic mice, where splenic B1 cells and IgM 
levels expand compared to WT mice. This could then provide an explanation why in 
Btg mice, where there is even further pressure on B1 cell numbers, a difference in B1 
cells and IgM levels is seen in females not males. This higher turnover in females 
could be explained by a higher clearance/degradation rate of IgM or a shorter 
lifespan of B1 plasma cells. Firstly, IgM clearance rate was investigated by 
transferring serum with antibodies of the ‘a’ heavy chain isotype (from Balb/c mice) 
into Apoe-/- mice, which express the ‘b’ heavy chain isotype, allowing quantification of 
injected IgMa by ELISA. The clearance of IgMa was tracked over 48h but we did not 
observe a difference in half-life between male and female Apoe-/- mice 
(Supplemental Figure VI-D). Secondly, in vitro, we assessed the ability of male and 
female B1 cells to form IgM secreting plasma cells in response to IL-5 and BAFF. 
We found a decreased ability of female B1 cells to produce IgM compared to males 
(figure 6C+D). Female B1 cells showed enhanced susceptibility to apoptosis, with 
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fewer female B1 cells than male B1 cells alive after overnight culture (staining 
negative for Annexin V and propidium iodide) (figure 6E).  Elispot assays for IgM 
demonstrated that female IgM ASC produce similar amounts of IgM per cell (spot 
size) (Supplemental Figure VI-E).  
Female FcγRIIbΔAP-1 mice were also different from male counterparts. Despite a 
similar decrease (to that seen in males) in FcγRIIb levels on GC B cells of female 
FcγRIIbΔAP-1 mice compared to control littermates (Supplemental Figure VIIA), there 
was no difference in proportions of GC B cells (Supplemental Figure VIIB), total 
IgG2c (Supplemental Figure VIIC) or total IgM (Supplemental Figure VIID), and 
consequently no difference in atherosclerosis (Supplemental Figure VIIE). Female 
Apoe-/- mice had higher proportions of GC B cells (compare figure 3B and 
Supplemental Figure VIIB), Tfh (Supplemental Figure VII F), increased anti-dsDNA 
autoantibodies (Supplemental Figure VII G) and increased IgG2c antibodies 
(Supplemental Figure VII H) compared to males, suggesting an already enhanced 
autoimmune susceptibility that may not be increased so easily as the males by the 
FcγRIIb mutation. 
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Discussion 
Systemic and local inflammation is increasingly accepted as a major independent 
driver of atherosclerotic cardiovascular disease. Inflammation can induce and 
accelerate autoimmune responses that contribute to local tissue damage and 
prevent resolution37. Here, we report the novel finding that B cell-intrinsic control of 
autoimmune GC responses by the IgG receptor FcγRIIb limits atherosclerotic plaque 
development in mice. Although a role for FcγRIIB has been previously reported, the 
influence and mechanism, and in particular the main cell type expressing FcγRIIB 
are not understood. Our results support a pathogenic role for GC-dependent 
responses and we propose that IgG2c class switching may be a key pathogenic 
pathway. In addition, 1) we reveal a potential explanation for the opposite effects on 
atherosclerosis observed in Fcgr2b-/- mice and other models modulating both B-1 
and B-2 cells, and 2) provide further support for the paradigm that autoimmune 
responses in mouse atherosclerosis, like in humans, are gender-dependent.  
Our study is the first to reveal the importance of B cell FcγRIIb in experimental 
atherosclerosis. In addition to plasma cell responses, FcγRIIb also controls the GC 
response and is especially important in limiting access by autoreactive B cells. Data 
from both models suggest that GC-dependent responses may promote 
atherosclerosis, consistent with previous data implicating the GC as pathogenic25, 38, 
39. Over-expression of FcγRIIb led to a decrease in GC B cells and GC-dependent 
IgG isotypes (Figure 2). More specifically, limiting FcγRIIb upregulation on GC B 
cells but not plasma cells, B-1 cells or MZ B cells led to increased atherosclerosis, 
associated with an enhanced GC response (Figure 3). Crucially, in FcγRIIbΔAP-1 mice 
we were not able to detect differences in effector T cell responses (except GC-
promoting Tfh) and only observed an increase in IgG2c antibodies, not IgG1. The 
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latter effect may reflect the relatively short duration of the experiments, Th2 
dependent IgG1 responses being more prevalent after prolonged high fat diet 40. 
IgG2c is known to have a particularly potent pro-inflammatory Fc receptor-binding 
profile34. The Fc portion of IgG2c has a much higher bias for binding to activating 
FcγRIV than inhibitory FcγRIIb. In vitro, FcγRIV binding stimulates pro-inflammatory 
cytokine production and T cell stimulatory function by macrophages and dendritic 
cells34, 41. Here, we found that moDCs like those found in plaques produced high 
levels of TNF in response to IgG2c when stimulated to upregulate FcγRIV with IFN-
γ. (Figure 4). In agreement with our studies, atherosclerotic macrophages/dendritic 
cells express FcγRIV42, 43 and the activatory: inhibitory FcγR ratio of inflammatory 
monocytes is increased in western diet compared to chow conditions (analysis of 
data from Kim et al43). We thus suggest that GC-derived antibodies such as IgG2c 
may have direct pro-atherogenic effects on plaque (or inflamed vessel) innate 
immune cells.  
The human equivalent of IgG2c – FcγRIV interactions is thought to be IgG1 – 
FcγRIIIA 11. Recently, a subset of human monocytes expressing the surface marker 
SLAN (SLAN monocytes) were found to express FcγRIIIA (CD16), be the most 
responsive to immune complexes, and make high levels of TNF in response to 
human IgG1 44. This same subset is most expanded in cardiovascular disease 
patients 45. Human IgG levels have been positively associated with cardiovascular 
risk, although not in all studies 46. As exemplified by this study and others 27, 33, 39, 
antibodies have multiple relevant functions and further work is needed to understand 
and isolate these individual influences.  
Multiple studies have investigated atherosclerosis using Fcg2rb-/- mice. In summary, 
although the B cell phenotype of increased IgG, and in most cases increased IgM, is 
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consistent across studies, other factors appear to be inconsistent and affected by the 
background strain of the mice, timings and/or methodology. Interestingly, although 
Merched et al 20 observed a big increase in IgG, they did not observe differences in 
IgM levels, which based on our studies would be consistent with the increased 
atherosclerosis they reported. Multiple explanations for the effects on atherosclerosis 
observed in Fcgr2b-/- mice are possible since several anti-inflammatory pathways 
(increased Treg, increased Th2 cells, an M1 to M2 switch in macrophages, cytokine 
production by macrophages) and pathogenic pathways (autoantibodies, increased 
CCL2, increased T cell infiltration, more IL-17 and IL-23, increased FcγRIII on 
macrophages) are implicated across the various studies. Ng et al 47 found a similar 
reduction in atherosclerosis in both standard and bone marrow transplant 
experiments, suggesting that hematopoietic cell FcγRIIb deficiency was a key player 
in that study. Gender was important in one study using Fcgr2b-/- mice 18, as observed 
in our study, but a similar effect was observed in both genders in another study 47. 
Since the anti-inflammatory pathways listed above are not B cell intrinsic, they are 
likely to have different gender dependency. For example, IFN-γ deficiency only 
reduced atherosclerosis in male but not female mice48. Here, we found that 
modulation of IgM levels occurred only in female Btg mice despite a similar effect in 
both males and females on FcγRIIB overexpression. FcγRIIb appeared less 
important for the GC response in females, which might be explained by the already 
increased GC levels and autoantibodies, consistent with the enhanced susceptibility 
to autoimmunity of females, both in mice and humans49. Both oestrogen and 
testosterone have been implicated in regulating B cells. For example, a recent study 
demonstrated testosterone regulation of BAFF production in the spleen is important 
in regulating the B cell compartment 50 and a complement-independent natural 
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antibody pathway for bacterial clearance is driven by oestrogen and is only effective 
in females51. In humans, Frostegård and colleagues report higher anti-
phosphorylcholine IgM levels in females in multiple cohorts52. Further studies 
investigating the differences between male and female B cell systems, in particular 
B-1 cells, will be necessary to better understand the gender-dependent regulation of 
B cell responses in atherosclerosis. 
In summary, our studies make further strides towards understanding B cell regulation 
of atherosclerosis and support the pathogenic involvement of an active, Th1-
polarised GC-dependent response controlled by FcγRIIb levels. Our data further 
supports an important influence of B1 cell derived IgM but also now suggest the 
relative importance of these responses is gender dependent. Given the enhanced 
adaptive response associated with vulnerable plaques53, targeting such responses 
may be a future therapeutic strategy. 
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Highlights 
 The inhibitory IgG receptor FcγRIIb controls B cell activation and plasma cell 
survival. 
 In atherosclerotic mice, specific modulation of B cell FcγRIIb expression levels 
reveals FcγRIIb suppresses a pathogenic (and pro-atherogenic) germinal center 
B cell response in male mice. 
 Germinal center B cells produce IgG2c antibodies that promote TNF production 
by monocyte-derived macrophages/dendritic cells via FcγRIV, equivalent to IgG1 
– FcγRIIIA in humans. 
 FcγRIIb also controls atheroprotective B1 cell responses; in female 
atherosclerotic mice this function is more dominant and FcγRIIb overexpression 
resulted in enhanced atherosclerosis. 
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Figure Legends 
 
Figure 1. B cell overexpression of FcγRIIb inhibits B cell activation and reduces 
atherosclerosis in males. A. Mean fluorescence intensity for anti-FcγRIIb staining on 
B cells (B220
+
 IgM
+
) or CD11b
+
 cells from Apoe
-/-
 or B
tg
 Apoe
-/-
 mice. B. Proliferation 
of purified B cells from Apoe
-/-
 or B
tg
 Apoe
-/-
 mice after 72h stimulation with anti-IgM 
whole IgG or Fab’ fragments. C. Levels of spleen B cell subsets (see methods and 
Figure S1) in Apoe
-/-
 or B
tg
 Apoe
-/-
 mice. T1 – Transitional stage 1, T2 – transitional 
stage 2, MZ – Marginal zone, FO - Follicular. D-E. Atherosclerosis quantified using Oil 
Red O-stained aortic root cryosections from male Ldlr
-/-
 mice transplanted with WT or 
B
tg
 bone marrow and fed western diet for 6 weeks (D; n=12/group) or Apoe
-/-
 or B
tg
 
Apoe
-/-
 mice after 6 or 12 weeks western diet (E, n=8-12/group). *p<0.05. Scale bar = 
100µm. 
Figure 2. Atherosclerotic B
tg
 mice display reduced IgG antibody responses. Antibody-
producing B cell subsets and serum antibody levels were quantified (by flow cytometry 
and ELISA, respectively) in tissues from western diet-fed Apoe
-/-
 or B
tg
 Apoe
-/-
 mice. 
A. Bone marrow plasma cells (B220
-
 CD138
hi
). Data from 1 Apoe
-/-
 mouse was 
excluded during data collection.  B+C. Total serum IgG and IgM levels. D. Spleen 
germinal center (GC) B cell levels (CXCR5
+
 GL7
+
). E. Spleen B1 cell levels (CD19
+
 
B220
+/lo
 IgM
+
 CD43
+
 CD23
-
). F+G. Total serum IgG2c and IgG1. Data from 1 Apoe
-/-
 
mouse was excluded during data collection. H. Serum MDA-LDL-binding IgG2c or 
IgG1. Data from 1 Apoe
-/-
 mouse was excluded during data collection. I. IgM antibodies 
to MDA-BSA, PC-BSA or the T15 idiotype (AB1-2 antibodies). *p<0.05. 
 
Figure 3. Decreased FcγRIIb expression on GC B Cells in FcγRIIb
ΔAP-1 
male mice 
enhances GC responses and increases atherosclerosis. A. Mean fluorescence 
intensity (MFI) of anti-FcγRIIb staining on B cells subsets (See figure S1) in Apoe
-/-
 or 
FcγRIIb
ΔAP-1
 Apoe
-/-
 mice. Sp – Spleen; BM – Bone marrow. B. Spleen GC B cell levels. 
C+D. Total serum IgG2c and IgG1. E. Atherosclerosis quantified using Oil Red O-
stained aortic root cryosections from male Apoe
-/-
 or FcγRIIb
ΔAP-1
 Apoe
-/-
 mice after 6 
weeks western diet. N=6-8/group. Scale bar = 100µm. F-H. Atherosclerotic plaque 
composition was analysed for proportions of cells (F) or MOMA2
+
 stained area (G). A 
single outlier was excluded from the WT group in F. *p<0.05. 
 
Figure 4. IgG2c induces TNF production by FcγRIV-expressing CD11b
+
 CD11c
+
 cells. 
A. Histograms of anti-FcgRIV staining on mouse blood myeloid cell subsets. B+C. 
Apoe
-/-
 (B) or Ldlr
-/- 
(C) mouse aortas were analysed by flow cytometry for FcyRIV 
mean fluorescent intensity (MFI) in myeloid cell subsets based on CD11b, CD11c and 
MHCII expression. D. GM-CSF-induced CD11c+ CD11b+ MHCII+ cells were 
incubated with IFNy for 24h then analysed by flow cytometry for FcyRI, FcyRIIb/III and 
FcgRIV. E. TNF production by GM-CSF-induced CD11c+ CD11b+ MHCII+ cells  after 
culture for 48h +/- IFN-γ on uncoated, mouse IgG2c or mouse IgG1-coated plates. 
Relative levels in 4 independent experiments. F. TNF production by IFN-γ-pretreated 
GM-CSF-induced CD11c+ CD11b+ MHCII+ cells  after culture for 48h with uncoated, 
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mouse IgG2c-coated or mouse IgG1-coated beads. Relative levels in 2 independent 
experiments. *p<0.05. 
 
Figure 5. B cell FcγRIIb expression levels are important for B1 cell responses in 
female atherosclerotic mice. A-C. B1 cells responses in tissues from western diet-fed 
female Apoe
-/-
 or B
tg
 Apoe
-/-
 mice. A. Spleen B1 cell levels (CD19
+
 B220
+/lo
 IgM
+
 CD43
+
 
CD23
-
). B. Total serum IgM levels. C. MDA-LDL binding IgM levels. D. Atherosclerosis 
quantified using Oil Red O-stained aortic root cryosections after 6 weeks western diet. 
N=7-8/group. *p<0.05. Scale bar = 100µm. 
 
Figure 6. B1 cells from female Apoe
-/-
 mice are more susceptible to apoptosis. A. 
Spleen B1 cell levels in male and female Apoe
-/-
 mice (CD19
+
 B220
+/lo
 IgM
+
 CD43
+
 
CD23
-
; pooled data from 4 experiments. B. Proportion of spleen B1 cells staining 
positive for Ki67 (relative to males, 4 experiments pooled). C. IgM production by 
purified B1 cells from male or female Apoe
-/-
 mice after 72h with IL-5 and BAFF 
(relative to males, 4 pooled experiments in at least duplicate). D. B1 cells purified from 
peritoneum of male or female Apoe
-/-
 mice were cultured with or without anti-FcγRIIB 
(2.4G2 antibody) then stained with annexin V and propidium iodide. Absolute numbers 
of remaining live cells (AnnV
-
 PI
-
) was quantified by flow cytometry using beads for 
normalization. *p<0.05. 
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Supplemental Figure I. Gating strategies used in flow cytometry. In some experiments, GC B cells 
were gated as B220+ IgM+ CD95+ GL7+. B1 cells are additionally CD19+ IgM+ B220lo.
Supplemental Figure II. A-D. Analysis of Ldlr-/- chimeric mice transplanted with WT control or Btg bone
marrow after 6 weeks western diet. A. Proportion of B cells expressing high levels of Fas (CD95hi GL7-).
****p<0.001. B. Serum total cholesterol. C. Body weight. D. Blood monocyte subsets (CD11b+ Ly6G-
CD115+ and Ly6C lo, int or hi) and neutrophils (CD11b+ Ly6G+). E-H. Analysis of Ldlr-/- chimeric mice
transplanted with WT control or FcγRIIb-macrophage transgenic (Mtg) bone marrow after 6 weeks
western diet. E. Mean flurorescent intensity for FcγRIIb on B cells and CD11b+ cells. **p<0.01. F.
Atherosclerotic plaque area. A single outlier was removed from the WT group. G. Macrophage
(MOMA2)-positive area of plaque. H. Serum total cholesterol.
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Supplemental Figure III. A-D. Analysis of Apoe-/- or Btg Apoe-/- mice after 6 or 12 weeks western
diet. A. Atherosclerosis quantified using Oil Red O-stained aortic root cryosections. B. Serum total
cholesterol. **p<0.01. C. Body weight. D. Blood monocyte subsets (CD11b+ Ly6G- CD115+ and Ly6C
lo, int or hi) and neutrophils (CD11b+ Ly6G+). E. Total cell numbers in spleens from each Btg cohort.
F. Bone marrow cell numbers in Apoe-/- or Btg Apoe-/- mice after 6 or 12 weeks western diet. G-J.
Analysis of atherosclerotic plaques for proportions of positive staining for MOMA2 (G), α-SMA (H),
necrotic core (I) or collagen (J) in aortic roots from Apoe-/- or Btg Apoe-/- mice after 12 weeks western
diet.
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Supplemental Figure IV. A+B. Levels of plaque CD3+ T cells in aortic roots from Ldlr-/- chimeric
mice transplanted with WT control or Btg bone marrow after 6 weeks western diet (A) or Apoe-/- or Btg
Apoe-/- mice after 12 weeks western diet (B). Data from 2 WT mice was excluded during data
collection (A). C-D. Proportion of spleen effector memory CD4+ T cells (CD3+ CD4+ CD62L- CD44hi)
in Ldlr-/- chimeric mice transplanted with WT control or Btg bone marrow after 6 weeks western diet
(C) or Apoe-/- or Btg Apoe-/- mice after 12 weeks western diet (D). E. Serum BAFF levels in Ldlr-/-
chimeric mice transplanted with WT control or Btg bone marrow after 6 weeks western diet. F-J.
Serum antibody titres in Ldlr-/- chimeric mice transplanted with WT control or Btg bone marrow after 6
weeks western diet. A single outlier was excluded from the WT group in H and I. *p<0.05.
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Supplemental Figure V. A-F. Analysis of male FcγRIIbBL6 Apoe-/- (BL6) or FcγRIIbΔAP-1 Apoe-/- (ΔAP-1)
mice after 6 weeks western diet. Proportions of spleen B cell subsets (see figure S1). B. Follicular
helper T cells (CD3+ CD4+ PD-1hi CXCR5hi). *p<0.05. C. Body weights. D. Serum total cholesterol. E.
Blood monocytes subsets (CD11b+ Ly6G- CD115+ and Ly6C lo, int or hi) and neutrophils (CD11b+
Ly6G+). F. Plaque CD3+ Cells.
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Supplemental Figure VI. A. B1 cells purified from peritoneum of Apoe-/- or Btg Apoe-/- mice were
cultured for 16h with or without anti-FcγRIIB (2.4G2 antibody) then stained with annexin V and
propidium iodide. Absolute numbers of remaining live cells (AnnV- PI-) was quantified by flow
cytometry using beads for normalization. B. Necrotic core area in aortic root plaques from female
Apoe-/- or Btg Apoe-/- mice after 6 weeks western diet. C. FcγRIIb levels on Spleen B1 cells in male
and female Apoe-/- or Btg Apoe-/- mice. D. IgM clearance rates determined after transfer of IgMa
serum (from Balb/c mice) into male or female Apoe-/- mice (each gender received gender matched
serum). E. Mean spot size of IgM-secreting spleen cells from male and female Apoe-/- mice analysed
by Elispot. Representative experiment of more than 5. *p<0.05.
Supplemental Figure VII. A-E. Analysis of Apoe-/- or FcγRIIbΔAP-1 Apoe-/- female mice after 6 weeks
western diet. A. Mean fluorescence intensity (MFI) of anti-FcγRIIb staining on follicular (FO) or
germinal center (GC) B cells from Apoe-/- or FcγRIIbΔAP-1 Apoe-/- female mice. B. Spleen GC B cell
levels. C. Total serum IgG2c. D. Total IgM levels. E. Atherosclerotic plaque area. N=6/group.
*p<0.05. F-H. Comparison of male and female Apoe-/- mice. F. Follicular helper T cells. G. Anti-
dsDNA IgG antiboides. H. Total IgG2c. *p<0.05; **p<0.01.
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Supplemental Table I
Target Clone Company
Ly6C 7/4 AbD Serotec
Ly-6G 1A8 BD
CD95 (Fas) Jo2 BD
CD11b M1/70 Biolegend
CD11c N418 Biolegend
CD16.2 9E9 Biolegend
CD43 Ly48 gp115 Biolegend
CD44 1M7 Biolegend
CD62L MEL-14 Biolegend
CD138 281-2 Biolegend
CD3 145-2C11 Biolegend
CD19 6D5 Biolegend
CXCR5 L138D7 Biolegend
PD-1 4B12 Biolegend
CD23 B3B4 Biolegend
CD16/32 93 Biolegend
MHCII M5/114.15.2 Biolegend
B220 RA3-6B2 Life Tech. 
CD4 RM4-5 Life Tech.
IgM II/41 Life Tech.
GL7 GL7 Life Tech.
CD21 4E3 Life Tech.
CD115 AFS98 Life Tech.
Ki67 SolA15 Life Tech.
CD64 REA286 Miltenyi
Supplemental Table II - Summary of effects of B cell FcγRIIB models on major parameters
FcγRIIb 
mutation
FcγRIIBBtg
(increased FcγRIIB on B cells)
FcγRIIBΔAP-1
(decreased FcγRIIb on GC B Cells)
Model Ldlr-/- Apoe-/- Apoe-/-
Gender Male Male Female Male Female
Parameter:
Plasma Cells n.d. ↓ ↓* ↔ ↔*
GC B Cells n.d. ↓ ↓* ↑ ↔
B1 Cells ↔* ↔ ↓ ↔ ↔*
IgG2c ↓ ↓ ↓* ↑ ↔
IgG1 ↓ ↓ ↓* ↔ ↔*
IgM ↔ ↔ ↓ ↑ ↔*
Teff ↓ ↓ ↓* ↔ ↔*
Atherosclerosis ↓ ↓ ↑ ↑ ↔
*Data not shown.
